Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $4.23 billion. The enterprise value is $3.54 billion.
| Market Cap | 4.23B |
| Enterprise Value | 3.54B |
Important Dates
The last earnings date was Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 193.77 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 193.77M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +4.70% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 53.99% |
| Float | 90.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 49.59 |
| PS Ratio | 3.33 |
| Forward PS | 2.58 |
| PB Ratio | 3.44 |
| P/TBV Ratio | 3.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.04, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.04 |
| Quick Ratio | 2.88 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.24 |
Financial Efficiency
Return on equity (ROE) is -8.08% and return on invested capital (ROIC) is -9.91%.
| Return on Equity (ROE) | -8.08% |
| Return on Assets (ROA) | -1.92% |
| Return on Invested Capital (ROIC) | -9.91% |
| Return on Capital Employed (ROCE) | -3.92% |
| Weighted Average Cost of Capital (WACC) | 6.40% |
| Revenue Per Employee | $428,803 |
| Profits Per Employee | -$30,860 |
| Employee Count | 2,965 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 14.32 |
Taxes
In the past 12 months, Legend Biotech has paid $35.30 million in taxes.
| Income Tax | 35.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.76% in the last 52 weeks. The beta is 0.39, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -38.76% |
| 50-Day Moving Average | 24.86 |
| 200-Day Moving Average | 23.65 |
| Relative Strength Index (RSI) | 49.55 |
| Average Volume (20 Days) | 2,972,590 |
Short Selling Information
The latest short interest is 18.11 million, so 22.31% of the outstanding shares have been sold short.
| Short Interest | 18.11M |
| Short Previous Month | 14.08M |
| Short % of Shares Out | 22.31% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.32 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $1.27 billion and -$91.50 million in losses. Loss per share was -$0.50.
| Revenue | 1.27B |
| Gross Profit | 719.30M |
| Operating Income | -52.80M |
| Pretax Income | -56.20M |
| Net Income | -91.50M |
| EBITDA | -41.60M |
| EBIT | -52.80M |
| Loss Per Share | -$0.50 |
Balance Sheet
The company has $964.60 million in cash and $278.20 million in debt, with a net cash position of $686.40 million or $3.54 per share.
| Cash & Cash Equivalents | 964.60M |
| Total Debt | 278.20M |
| Net Cash | 686.40M |
| Net Cash Per Share | $3.54 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 6.35 |
| Working Capital | 823.80M |
Cash Flow
In the last 12 months, operating cash flow was -$89.40 million and capital expenditures -$32.40 million, giving a free cash flow of -$121.80 million.
| Operating Cash Flow | -89.40M |
| Capital Expenditures | -32.40M |
| Depreciation & Amortization | 11.20M |
| Net Borrowing | -47.80M |
| Free Cash Flow | -121.80M |
| FCF Per Share | -$0.63 |
Margins
Gross margin is 56.58%, with operating and profit margins of -4.15% and -7.20%.
| Gross Margin | 56.58% |
| Operating Margin | -4.15% |
| Pretax Margin | -4.42% |
| Profit Margin | -7.20% |
| EBITDA Margin | -3.27% |
| EBIT Margin | -4.15% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.92% |
| Shareholder Yield | -0.92% |
| Earnings Yield | -2.16% |
| FCF Yield | -2.88% |
Analyst Forecast
The average price target for Legend Biotech is $49.25, which is 125.71% higher than the current price. The consensus rating is "Buy".
| Price Target | $49.25 |
| Price Target Difference | 125.71% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 26.30% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 5.57 and a Piotroski F-Score of 2.
| Altman Z-Score | 5.57 |
| Piotroski F-Score | 2 |